---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-014234"
form_type: "8-K"
ticker: "HROW"
cik: "0001360214"
company_name: "HARROW, INC."
filed_at: "2025-06-09T23:59:59+00:00"
generated_at: "2026-05-19T16:55:47.523155+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Harrow licenses exclusive U.S. rights to BYQLOVI ophthalmic steroid from Formosa

## Summary
- Upfront payment of $500,000 at first commercial sale; additional milestone payments and royalties on gross profits.
- BYQLOVI is first new ophthalmic steroid class in over 15 years; FDA-approved for post-op inflammation/pain.
- Expected launch in Q4 2025; U.S. market exceeds 7M annual ophthalmic surgeries.
- Clinical data: 77-85% pain-free at Day 4; 1.4% elevated IOP; BID dosing 14 days without loading/maintenance.
- Formulated with Formosa's proprietary APNT nanoparticle technology.

## SEC filing metadata
- accession: 0001641172-25-014234
- form_type: 8-K
- ticker: HROW
- cik: 0001360214
- company_name: HARROW, INC.
- filed_at: 2025-06-09T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1360214/000164117225014234/0001641172-25-014234-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1360214/000164117225014234/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-014234
- JSON: https://secwatch.observer/filing/0001641172-25-014234.json
- Plain text: https://secwatch.observer/filing/0001641172-25-014234.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.